RGEN News and Press, Repligen Corporation From 12/21/22

Summary A 3-5 month prospect from here of RGEN share prices could reasonably range from a $156.4 low to a $190.62 high from its present $162.42 price, a +17.4% gain. 88 positions like today’s in the past 5 years of 1261 market days resulted in 12.1% average net gains each during ...

Repligen Corporation (RGEN) Q3 2022 Earnings Conference Call November 1, 2022 08:30 AM ET Company Participants Sondra Newman – Head-Investor Relations Tony Hunt – President and Chief Executive Officer Jon Snodgres – Chief Financial Officer ...

Repligen press release ( NASDAQ: RGEN ): Q3 Non-GAAP EPS of $0.77 beats by $0.09 . Revenue of $200.7M (+12.6% Y/Y) beats by $9.2M . Gross margin for the third quarter of 2022 was 56.9%, compared to 57.6% for the third quarter of 2021. Adjusted gross margin ...

Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Delivers base business growth of 29% for the quarter Expands Process Analytics portfolio with DRS Daylight Solutions agree...

WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (“Purolite”), for the development and manufacturing of affinity ligands focused on monoclon...

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2022 financial results on Tuesday, November 1, 2022. The Company will issue a press release before the market opens and will host a conference ...

Summary Biotech stocks’ bad investment reputations often (not always) come from failed lab tests. But today’s opportunity comes from overenergetic market correction. A week ago I highlighted BGNE as the most opportune biotech stock for near-term capital gain. Forecas...

Repligen ( NASDAQ: RGEN ) said it had entered into a partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market. Under the deal, Repligen will commercialize Culpeo, as well as de...

WALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand th...

The biotech industry is heavily regulated by the federal government and its science watchdog, the Food and Drug Administration (FDA). As a consequence, biotech investors often evaluate a possible investment by looking at the company's pipeline of future assets. Research and development is a...